Related Experiment Video
Updated: Mar 25, 2026

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
Published on: January 31, 2018
Poly(ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis: Mechanism and Potential Role for PARP Inhibitors
Ioannis C Kotsopoulos1, Ali Kucukmetin, Asima Mukhopadhyay
1*Northern Gynaecological Oncology Centre, Queen Elizabeth Hospital, Gateshead; and †Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom.
Abstract:
Treatment options for disease recurrence of women treated for locally advanced and advanced cervical cancer are very limited-largely palliative chemotherapy. The low efficacy of the currently available drugs raises the need for new targeted agents. Poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors (PARPi) have emerged as a promising class of chemotherapeutic agents in cancers associated with defects in DNA repair. Their therapeutic potential in cervical cancer is currently being evaluated in 3 ongoing clinical trials. Here we review the available information regarding all the aspects of PARP in cervical intraepithelial neoplasia and invasive cervical cancer, from expression and the mechanism of action to the role of the polymorphisms in the pathogenesis of the disease, as well as the potential of the inhibitors. We finally propose a new unifying theory regarding the role of PARPs in the development of cervical carcinomas.
Insights
Poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors show promise for treating advanced cervical cancer, offering a targeted approach beyond palliative chemotherapy. Research is ongoing to evaluate their efficacy and role in cervical carcinomas.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Limited treatment options exist for recurrent advanced cervical cancer, primarily palliative chemotherapy with low efficacy.
- There is a critical need for novel targeted therapeutic agents.
- Poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors (PARPi) are a promising class of agents for DNA repair-deficient cancers.
Purpose of the Study:
- To review the role of PARP in cervical intraepithelial neoplasia and invasive cervical cancer.
- To explore PARP expression, mechanism of action, and the impact of polymorphisms in cervical cancer pathogenesis.
- To evaluate the therapeutic potential of PARP inhibitors in cervical cancer.
Main Methods:
- Comprehensive literature review of existing studies on PARP and PARPi in cervical cancer.
- Analysis of PARP expression, function, and genetic polymorphisms.
- Evaluation of data from ongoing clinical trials of PARPi in cervical cancer.
Main Results:
- PARP plays a significant role in cervical cancer development and progression.
- PARPi demonstrate therapeutic potential, with several clinical trials underway.
- Understanding PARP's role may lead to new treatment strategies.
Conclusions:
- PARP inhibitors represent a promising targeted therapy for advanced and recurrent cervical cancer.
- Further research and clinical trials are essential to establish the efficacy of PARPi.
- A new unifying theory on the role of PARPs in cervical carcinoma development is proposed.
More Related Videos
06:44Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging
Published on: April 28, 2021
04:07Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
Published on: February 24, 2023
Related Concept Videos
Restarting Stalled Replication Forks
Inhibition of Cdk Activity
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Negative Regulator Molecules
Abnormal Proliferation